Category: angioplasty
CHICAGO --- The largest national stem cell study for heart disease showed the first evidence that transplanting a potent form of adult stem cells into the heart muscle of subjects with severe angina results in less pain and an improved ability to walk. The transplant subjects also experienced fewer deaths than those who didn't receive stem cells.
STANFORD, Calif. -- Many patients with diabetes should forego angioplasties for heart disease and just take medicine instead, according to a new National Institutes of Health study led by Stanford University School of Medicine researcher Mark Hlatky, MD.
Edmonton − More than half of patients with acute coronary syndrome (ACS) don't get any counselling on their ability to drive after angioplasty -- and this could be putting lives in danger, D
Edmonton − The gender difference between men and women is a lot smaller than we've been led to believe when it comes to heart attack symptoms, according to a new study presented to the Canadi
DURHAM, N.C. -- Imagine a surgical patient on a blood-thinning drug who starts bleeding more than expected, and an antidote that works immediately -- because the blood thinner and antidote were designed to work together.
SAN FRANCISCO, CA -- SEPTEMBER 25, 2009 -- Late-breaking data from the landmark HORIZONS-AMI clinical trial, presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, demonstrated that after two years, in heart attack patients, the use of a drug-eluting stent (paclitaxel) was safer and more effective than a bare-metal stent; and that the administration
SAN FRANCISCO, CA -- SEPTEMBER 21, 2009 -- Two subset analyses from the landmark HORIZONS-AMI trial show that the anticoagulant bivalirudin lowers major bleeding and cardiac death versus the combination of heparin and a GP IIb/IIIa inhibitor in patients with ST-segment myocardial infarction (STEMI) who have disease of the left anterior descending artery (LAD), while in STEMI patients at highe
Barcelona, Spain, 1 September: Acute myocardial infarction (AMI) remains one of the leading causes of death in the Western world, with prevalence predicted to increase dramatically in developing countries, especially India and China. Around 40-50% of AMIs are the result of a persistent, complete thrombotic occlusion of a coronary artery.
Barcelona, Spain, 1 September: Primary angioplasty (with stent implantation) is the most effective therapy for acute myocardial infarction (AMI), but it is not available to many patients, even though most European countries have sufficient resources (ie, catheterisation laboratories) for its wider use.
Primary angioplasty may be more effective than thrombolysis in very elderly patients with AMI: results from the TRIANA trial
Barcelona, Spain, August 30: Data from a phase II trial of an investigational intravenous drug designed to block the formation of blood clots shows potential to reduce the risk of death, a second heart attack, or other coronary complications compared with the current standard of care in patients presenting with acute coronary syndromes (heart attacks or unstable angina).
Barcelona, Spain, 30 August: A landmark international study led by McMaster University researchers found high doses of the blood thinner clopidogrel (Plavix) significantly reduce complications in heart patients undergoing angioplasty to clear blocked arteries.
Barcelona, Spain, 31 August: A new trial has begun in order to ascertain once and for all whether the best strategy for patients who cannot receive P-PCI is early fibrinolysis, together with mandated angiography. This is the STREAM trial whose principal investigators are Profs Frans van der Werf, Paul Armstrong and Tony Gershlick.
A novel drug that targets a master disease-causing gene can dramatically reduce heart muscle damage after a heart attack and may lead to significantly improved patient outcomes, researchers at the University of New South Wales (UNSW) have shown.
SAN ANTONIO, Texas, U.S.A. -- The giant monoliths of Easter Island are worn, but they have endured for centuries. New research suggests that a compound first discovered in the soil of the South Pacific island might help us stand the test of time, too.
